Veru Narrows Q3 Loss, Fully Enrolls Obesity Trial, and Secures Key Patent Allowance
VERU sits 17% above its 52-week low of $2.05 on light trading volume (0.1× avg).
Summary
A narrower Q3 loss, full enrollment of 239 patients in the Phase 2b obesity trial, and a key patent allowance all signal positive momentum ahead of the Q1 2027 interim data readout.
Key Events · Earnings and Guidance · VERU
-
Q3 Loss Narrows
Net loss of $7.0M ($0.30/share) vs. $7.3M ($0.50/share) a year ago; R&D rose to $4.4M, G&A fell to $3.4M.
-
Phase 2b Trial Fully Enrolled
PLATEAU study enrolled 239 patients, exceeding the 200-patient target; interim analysis on track for Q1 2027, topline data Q4 2027.
-
Key Patent Allowance
USPTO notice of allowance for enobosarm+semaglutide combination patent, extending U.S. protection to at least October 2044.
-
Cash Runway
Cash of $23.9M as of June 30, 2026, up from $15.8M at fiscal year-end, providing funding into 2027.
Analysis · VERU · Life Sciences
Fiscal Q3 results show a narrowed net loss of $7.0M ($0.30/share) compared with $7.3M a year ago, while cash of $23.9M extends the runway into 2027. The Phase 2b PLATEAU obesity trial has fully enrolled 239 patients — exceeding the 200-patient target — keeping the interim readout on track for Q1 2027. A USPTO notice of allowance for a key enobosarm+semaglutide patent strengthens IP protection to at least 2044, enhancing the asset's value. Together, these updates reduce near-term clinical risk and reinforce the investment thesis ahead of the pivotal interim analysis.
At the time of this filing, VERU was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.4M. The 52-week trading range was $2.05 to $7.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.